Kiniksa Pharmaceuticals International, plc (KNSA) vs Neurocrine Biosciences, Inc. (NBIX)
- Kiniksa Pharmaceuticals International, plc KNSA 78.59 −1.69%
- Neurocrine Biosciences, Inc. NBIX 135.71 −0.91%
Kiniksa Pharmaceuticals International, plc and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Neurocrine Biosciences, Inc. is the larger, with a market value of $13.9B against $6.2B — 2.2× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 19.2× against 73.4×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.9% against 34.4%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs 9.59%) and the lower return on invested capital (15.0% vs 48.9%). Across the 20 metrics below, Neurocrine Biosciences, Inc. leads on 15 and Kiniksa Pharmaceuticals International, plc on 5.
Valuation
Profitability
| Metric | KNSA | NBIX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 89.82% | 97.94% | 53.94% |
| Operating margin | 11.92% | 23.56% | 0.00% |
| Net margin | 9.59% | 20.91% | 0.00% |
| Free cash flow margin | 21.74% | 25.80% | 0.00% |
| Return on equity | 14.04% | 22.09% | (0.40%) |
| Return on assets | 10.36% | 15.26% | (3.32%) |
| Return on invested capital | 48.87% | 15.04% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack